Ovemotide

DB19156InvestigationalProtein Based Therapies

Ovemotide is under investigation in clinical trial NCT00357461 (Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma).

Mechanism: Pharmacologically active on MHC class I HLA-A protein
Curator reviewed
Also known as: (264-l-valine)melanocyte protein pmel 17 (human melanoma-associated me20 antigen)-(256-264)-peptide · Elagigiltv · Gp100:280-288(288V) peptide · L-valine, l-tyrosyl-l-leucyl-l-.alpha.-glutamyl-l-prolylglycyl-l-prolyl-l-valyl-l-threonyl- · MART-1:26-35(27L) peptide
Code names: (LEU27)-MELAN-A, MART 1 (26-35) · MELAN-A(AA26-35*A27L)) · MPS-21

Resolves to

Compound

UNII704120HM0HCAS181477-91-8

Clinical / RWD

RxNorm1427208

Targets

P79603HLA-A*02

What you can answer from here — as of September 25, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Ovemotide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account